Abstract
After a brief historical introduction to Council Directives relating to the manufacture of radiopharmaceuticals the work of the Association of Radiopharmaceuticals Producers — Europe (ARPE) is discussed. ARPE has played a significant role as an officially recognized interlocutor with the EEC, influencing decisions on the registration of radiopharmaceuticals and labelling; this role is reviewed and difficulties identified. The future of radiopharmaceuticals is then considered; it is emphasized that harmonization of national laws by the European Council would represent a first step to enabling radiopharmaceutical manufacturers to access the largest possible market for their products.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fallais, C.J., Sivewright, S. & Ogle, J.R. The radiopharmaceutical industry and European Union regulations. Eur J Nucl Med 24, 77–79 (1997). https://doi.org/10.1007/BF01728314
Issue Date:
DOI: https://doi.org/10.1007/BF01728314